Liraglutide Research for Type 2 Diabetes
An evidence-based overview of research examining Liraglutide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
Liraglutide is FDA-approved for glycemic control in type 2 diabetes. The LEAD program (6 Phase 3 RCTs, >4,000 patients) demonstrated HbA1c reductions of 1.0-1.5% with weight loss rather than weight gain. LEADER trial (N=9,340) showed 13% reduction in major cardiovascular events.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Type 2 Diabetes
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Liraglutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.